Luoheng Qin

Luoheng Qin has extensive experience in medicinal chemistry, with a focus on oncology and metabolic diseases. Luoheng currently holds the position of Director of Medicinal Chemistry at Insilico Medicine since January 2021. Prior to this, they worked as a Senior Group Lead at Jiangsu Hansoh Pharmaceutical Group Co., Ltd. from January 2020 to January 2021. Before that, Luoheng Qin was a Senior Scientist and Project Leader at The Janssen Pharmaceutical Companies of Johnson & Johnson from November 2016 to January 2020. At Janssen, they played key roles in optimizing pharmacokinetic profiles, mitigating toxicity issues, and leading the SAR evolution of various oncology projects. Earlier in their career, Luoheng Qin worked as a Scientist II at Eli Lilly from September 2012 to November 2016, where they made significant contributions to the discovery of preclinical candidates for enzyme and GPCR projects in the field of metabolic diseases.

Luoheng Qin completed a Bachelor of Science (B.S.) in Chemistry at Fudan University from 2003 to 2007. Following that, from 2007 to 2012, Luoheng Qin pursued and earned a Doctor of Philosophy (Ph.D.) degree in Chemistry from Boston College.